Parmax Pharma share news, announcements and annual reports
BSE: 540359Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 26 Oct 2026. Previous close ₹136.40.
26 Oct: open ₹135.05, high ₹135.05, low ₹135.05
- Under BSE's graded surveillance, stage 0, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹93 Cr4,411th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −70.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 657
Parmax Pharma has 390 announcements on record, routine notices left out; 2 in the 30 days to 1 Nov 2026, the latest on 28 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Parmax Pharma quarterly results
The board met on 14 Aug 2026 to consider quarterly results
Notice filed 11 Aug 2026
Parmax Pharma annual reports, presentations and earnings calls
The company's own documents, latest first.Parmax Pharma financials, year by year
Annual reports14
- Annual Report of Financial Year 2025-26 along with Notice of Annual General Meeting7 Sep 2026
- Annual Report for FY 2024-256 Sep 2025
- Annual Report of the PARMAX PHARMA LIMITED for the financial year 2023-24.6 Sep 2024
- Annual Report for FY 2022-23.4 Sep 2023
- Annual report, year to Mar 20228 Sep 2022
9 earlier reports
- Annual report, year to Mar 202128 Aug 2021
- Annual report, year to Mar 202025 Sep 2020
- Annual report, year to Mar 20198 Sep 2019
- Annual report, year to Mar 201828 Sep 2018
- Annual report, year to Mar 201726 Sep 2017
- Annual report, year to Mar 2016Filing day not known
- Annual report, year to Mar 2015Filing day not known
- Annual report, year to Mar 2014Filing day not known
- Annual report, year to Mar 2013Filing day not known
Parmax Pharma share news and announcements
Newest first. Page 1 of 8.
Oct 2026
28 Oct · Management
8 Oct · Management
1 Oct · Meeting
Sep 2026
29 Sep · Meeting
28 Sep · Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 - Intimation Of Fire Incident At The Plant Of The Company
7 Sep · Meeting
Aug 2026
29 Aug · Announcement under Regulation 30 (LODR)-Allotment
24 Aug · Intimation Of Reclassification Of Promoters Under Regulation 31A Of SEBI (LODR) Regulations, 2015
24 Aug · Post Offer Advertisement
22 Aug · Business
14 Aug · Results
14 Aug · Results
11 Aug · Board meeting
Meeting on 14 Aug 2026: quarterly results
Jul 2026
29 Jul · Updates on Open Offer
27 Jul · Updates on Open Offer
3 Jul · Meeting
2 Jul · Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
2 Jul · Meeting
Jun 2026
23 Jun · Meeting
23 Jun · Draft Letter of Offer
15 Jun · Detailed Public Statement
9 Jun · Meeting
9 Jun · Business
8 Jun · Board meeting
3 Jun · Board meeting
Meeting on 8 Jun 2026: preferential issue of shares and issue of warrants3 Jun · Results
1 Jun · Board meeting
Meeting on 2 Jun 2026: audited results
May 2026
31 May · Meeting
28 May · Meeting
Mar 2026
25 Mar · Management
Feb 2026
14 Feb · Results
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 12 Oct 2026Board or managers changeddown 0.97%−0.3 pts vs Nifty 500market median 0.0% · volume 0.2× usual · The announcement
- 17 Aug 2026Board or managers changedup 2.00%+2.1 pts vs Nifty 500market median 0.0% · five sessions +10.3% (+10.6 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 4 May 2026Board or managers changedup 8.26%+7.6 pts vs Nifty 500market median 0.0% · five sessions +9.9% (+8.0 pts vs Nifty 500) · volume 0.5× usual · The announcement
- 18 Aug 2025Board or managers changeddown 5.92%−7.0 pts vs Nifty 500market median 0.0% · five sessions −4.5% (−5.9 pts vs Nifty 500) · volume 0.4× usual · The announcement
- 14 Aug 2025Board or managers changedup 6.61%+6.7 pts vs Nifty 500market median 0.0% · five sessions +0.7% (−1.2 pts vs Nifty 500) · volume 1.9× usual · The announcement
- 2 Jul 2025Board or managers changeddown 2.95%−2.7 pts vs Nifty 500market median 0.0% · five sessions +6.7% (+6.9 pts vs Nifty 500) · volume 0.4× usual · The announcement
- 16 Aug 2024Board or managers changedup 0.94%−0.8 pts vs Nifty 500market median 0.0% · five sessions +3.2% (−0.2 pts vs Nifty 500) · volume 0.3× usual · The announcement
- 1 Feb 2024Board or managers changeddown 3.79%−3.7 pts vs Nifty 500market median 0.0% · five sessions −2.4% (−3.9 pts vs Nifty 500) · volume 0.6× usual · The announcement
- 27 Apr 2023Board or managers changedup 3.05%+2.5 pts vs Nifty 500market median 0.0% · five sessions +3.2% (+0.4 pts vs Nifty 500) · volume 1.0× usual · The announcement
- 8 Feb 2021Board or managers changedup 3.34%−2.4 pts vs Nifty 500market median 0.0% · five sessions −6.5% (−13.3 pts vs Nifty 500) · volume 0.9× usual · The announcement